Top Markets
#1 Islamic Coin Islamic Coin +93.16%
#2 龙虾 (Lobster) 龙虾 (Lobster) +69.97%
#3 Tokenlon Tokenlon +67.84%
#4 Lisk Lisk +50.13%
#5 VeThor VeThor +25.87%
#6 Nockchain Nockchain +19.50%
#7 Collector Crypt Collector Crypt +15.40%
#8 Mubarak Mubarak +14.45%
#9 PumpMeme PumpMeme +12.92%
#10 UnifAI Network UnifAI Network +11.05%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Rank in Stocks #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Share Price
$17.82
Last synced: 2026-09-11
Market Cap
$32.43B
Change (1 day)
0.83%
Change (1 year)
-25.31%
Country
JP
Trade Daiichi Sankyo Company, Limited (4568)

Category

Healthcare
Revenue for Daiichi Sankyo Company, Limited (4568)
Revenue in Jun 2026 TTM: $14.75B
According to Daiichi Sankyo Company, Limited latest financial reports the company's current revenue (TTM) is $14.75B. In 2024 the company made a revenue of $10.58B an increase over the revenue in the year 2023 that was $9.63B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Daiichi Sankyo Company, Limited from 2000 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $14.75B 17.20%
2025 $12.58B 18.91%
2024 $10.58B 9.90%
2023 $9.63B 12.20%
2022 $8.58B -1.25%
2021 $8.69B -4.84%
2020 $9.13B 9.03%
2019 $8.38B -7.32%
2018 $9.04B 5.39%
2017 $8.58B -2.19%
2016 $8.77B 14.38%
2015 $7.67B -29.30%
2014 $10.84B 2.39%
2013 $10.59B -6.41%
2012 $11.31B -3.05%
2011 $11.67B 14.54%
2010 $10.19B 19.06%
2009 $8.56B -3.04%
2008 $8.83B 12.02%
2007 $7.88B 0.11%
2006 $7.87B 43.33%
2005 $5.49B -4.11%
2004 $5.73B 18.80%
2003 $4.82B 16.37%
2002 $4.14B -4.69%
2001 $4.35B -24.27%
2000 $5.74B 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B 440.19%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B 564.03%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B 336.59%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B 425.63%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B 350.24%
US